Rescue from failed growth factor and/or chemotherapy HSC mobilization with G-CSF and plerixafor (AMD3100): An institutional experience

C. J. Fowler, A. Dunn, Brandon Hayes-Lattin, K. Hansen, L. Hansen, K. Lanier, V. Nelson, T. Kovacsovics, J. Leis, G. Calandra, Richard Maziarz

Research output: Contribution to journalArticle

61 Citations (Scopus)

Abstract

Auto-SCT has been shown to be a potentially curative treatment for a variety of hematological malignancies. Auto-SCT is dependent on the successful mobilization and collection of hematopoietic stem cells to ensure engraftment. The inability to mobilize sufficient number of hematopoietic stem cells using standard cytokine-assisted mobilization strategies excludes eligible patients from potentially curative auto-SCT. Plerixafor (AMD3100; Mozobil), a novel bicyclam antagonist of the SDF-1α/CXCR4 complex, has been reported previously to augment PBSC mobilization in patients undergoing their first planned stem cell mobilization and collection attempt. In our experience, 17 of 20 patients otherwise eligible for auto-SCT who failed previous mobilization attempts had successful mobilization of CD34+ hematopoietic stem cells with one apheresis procedure, and an additional patient required two aphereses procedures, when treated with the combination of plerixafor and G-CSF on a compassionate use protocol available at our institution.

Original languageEnglish (US)
Pages (from-to)909-917
Number of pages9
JournalBone Marrow Transplantation
Volume43
Issue number12
DOIs
StatePublished - 2009

Fingerprint

Granulocyte Colony-Stimulating Factor
Hematopoietic Stem Cell Mobilization
Intercellular Signaling Peptides and Proteins
Drug Therapy
Blood Component Removal
Compassionate Use Trials
Hematologic Neoplasms
Hematopoietic Stem Cells
JM 3100
Cytokines

ASJC Scopus subject areas

  • Hematology
  • Transplantation

Cite this

Rescue from failed growth factor and/or chemotherapy HSC mobilization with G-CSF and plerixafor (AMD3100) : An institutional experience. / Fowler, C. J.; Dunn, A.; Hayes-Lattin, Brandon; Hansen, K.; Hansen, L.; Lanier, K.; Nelson, V.; Kovacsovics, T.; Leis, J.; Calandra, G.; Maziarz, Richard.

In: Bone Marrow Transplantation, Vol. 43, No. 12, 2009, p. 909-917.

Research output: Contribution to journalArticle

Fowler, C. J. ; Dunn, A. ; Hayes-Lattin, Brandon ; Hansen, K. ; Hansen, L. ; Lanier, K. ; Nelson, V. ; Kovacsovics, T. ; Leis, J. ; Calandra, G. ; Maziarz, Richard. / Rescue from failed growth factor and/or chemotherapy HSC mobilization with G-CSF and plerixafor (AMD3100) : An institutional experience. In: Bone Marrow Transplantation. 2009 ; Vol. 43, No. 12. pp. 909-917.
@article{5ac662f46fb04a8183ee374477189295,
title = "Rescue from failed growth factor and/or chemotherapy HSC mobilization with G-CSF and plerixafor (AMD3100): An institutional experience",
abstract = "Auto-SCT has been shown to be a potentially curative treatment for a variety of hematological malignancies. Auto-SCT is dependent on the successful mobilization and collection of hematopoietic stem cells to ensure engraftment. The inability to mobilize sufficient number of hematopoietic stem cells using standard cytokine-assisted mobilization strategies excludes eligible patients from potentially curative auto-SCT. Plerixafor (AMD3100; Mozobil), a novel bicyclam antagonist of the SDF-1α/CXCR4 complex, has been reported previously to augment PBSC mobilization in patients undergoing their first planned stem cell mobilization and collection attempt. In our experience, 17 of 20 patients otherwise eligible for auto-SCT who failed previous mobilization attempts had successful mobilization of CD34+ hematopoietic stem cells with one apheresis procedure, and an additional patient required two aphereses procedures, when treated with the combination of plerixafor and G-CSF on a compassionate use protocol available at our institution.",
author = "Fowler, {C. J.} and A. Dunn and Brandon Hayes-Lattin and K. Hansen and L. Hansen and K. Lanier and V. Nelson and T. Kovacsovics and J. Leis and G. Calandra and Richard Maziarz",
year = "2009",
doi = "10.1038/bmt.2008.409",
language = "English (US)",
volume = "43",
pages = "909--917",
journal = "Bone Marrow Transplantation",
issn = "0268-3369",
publisher = "Nature Publishing Group",
number = "12",

}

TY - JOUR

T1 - Rescue from failed growth factor and/or chemotherapy HSC mobilization with G-CSF and plerixafor (AMD3100)

T2 - An institutional experience

AU - Fowler, C. J.

AU - Dunn, A.

AU - Hayes-Lattin, Brandon

AU - Hansen, K.

AU - Hansen, L.

AU - Lanier, K.

AU - Nelson, V.

AU - Kovacsovics, T.

AU - Leis, J.

AU - Calandra, G.

AU - Maziarz, Richard

PY - 2009

Y1 - 2009

N2 - Auto-SCT has been shown to be a potentially curative treatment for a variety of hematological malignancies. Auto-SCT is dependent on the successful mobilization and collection of hematopoietic stem cells to ensure engraftment. The inability to mobilize sufficient number of hematopoietic stem cells using standard cytokine-assisted mobilization strategies excludes eligible patients from potentially curative auto-SCT. Plerixafor (AMD3100; Mozobil), a novel bicyclam antagonist of the SDF-1α/CXCR4 complex, has been reported previously to augment PBSC mobilization in patients undergoing their first planned stem cell mobilization and collection attempt. In our experience, 17 of 20 patients otherwise eligible for auto-SCT who failed previous mobilization attempts had successful mobilization of CD34+ hematopoietic stem cells with one apheresis procedure, and an additional patient required two aphereses procedures, when treated with the combination of plerixafor and G-CSF on a compassionate use protocol available at our institution.

AB - Auto-SCT has been shown to be a potentially curative treatment for a variety of hematological malignancies. Auto-SCT is dependent on the successful mobilization and collection of hematopoietic stem cells to ensure engraftment. The inability to mobilize sufficient number of hematopoietic stem cells using standard cytokine-assisted mobilization strategies excludes eligible patients from potentially curative auto-SCT. Plerixafor (AMD3100; Mozobil), a novel bicyclam antagonist of the SDF-1α/CXCR4 complex, has been reported previously to augment PBSC mobilization in patients undergoing their first planned stem cell mobilization and collection attempt. In our experience, 17 of 20 patients otherwise eligible for auto-SCT who failed previous mobilization attempts had successful mobilization of CD34+ hematopoietic stem cells with one apheresis procedure, and an additional patient required two aphereses procedures, when treated with the combination of plerixafor and G-CSF on a compassionate use protocol available at our institution.

UR - http://www.scopus.com/inward/record.url?scp=67649980456&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=67649980456&partnerID=8YFLogxK

U2 - 10.1038/bmt.2008.409

DO - 10.1038/bmt.2008.409

M3 - Article

C2 - 19182831

AN - SCOPUS:67649980456

VL - 43

SP - 909

EP - 917

JO - Bone Marrow Transplantation

JF - Bone Marrow Transplantation

SN - 0268-3369

IS - 12

ER -